FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21, 2026
August 21, 2026
WASHINGTON, Aug. 21 -- The Federal Trade Commission issued the following news release:
* * *
FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
*
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel-a drug used to treat rheumatoid arthritis and other inflammatory conditions-allowi . . .
* * *
FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
*
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel-a drug used to treat rheumatoid arthritis and other inflammatory conditions-allowi . . .